Anna F Delgado1, Alberto F Delgado2. 1. From the Department of Clinical Neuroscience (Anna F.D.), Karolinska Institute, Stockholm, Sweden. 2. Department of Surgical Sciences (Alberto F.D.), Uppsala University, Uppsala, Sweden.
Abstract
BACKGROUND: DSC perfusion has been evaluated in the discrimination between low-grade and high-grade glioma but the diagnostic potential to discriminate beween glioma grades II and III remains unclear. PURPOSE: Our aim was to evaluate the diagnostic accuracy of relative maximal CBV from DSC perfusion MR imaging to discriminate glioma grades II and III. DATA SOURCES: A systematic literature search was performed in PubMed/MEDLINE, Embase, Web of Science, and ClinicalTrials.gov. STUDY SELECTION: Eligible studies reported on patients evaluated with relative maximal CBV derived from DSC with a confirmed neuropathologic diagnosis of glioma World Health Organization grades II and III. Studies reporting on mean or individual patient data were considered for inclusion. DATA ANALYSIS: Data were analyzed by using inverse variance with the random-effects model and receiver operating characteristic curves describing optimal cutoffs and areas under the curve. Bivariate diagnostic random-effects meta-analysis was used to calculate diagnostic accuracy. DATA SYNTHESIS: Twenty-eight studies evaluating 727 individuals were included in the meta-analysis. Individual data were available from 10 studies comprising 190 individuals. The mean difference of relative maximal CBV between glioma grades II and III (n = 727) was 1.76 (95% CI, 1.27-2.24; P < .001). Individual patient data (n = 190) had an area under the curve of 0.77 for discriminating glioma grades II and III at an optimal cutoff of 2.02. When we analyzed astrocytomas separately, the area under the curve increased to 0.86 but decreased to 0.61 when we analyzed oligodendrogliomas. LIMITATIONS: A substantial heterogeneity was found among included studies. CONCLUSIONS: Glioma grade III had higher relative maximal CBV compared with glioma grade II. A high diagnostic accuracy was found for all patients and astrocytomas; however, the diagnostic accuracy was substantially reduced when discriminating oligodendroglioma grades II and III.
BACKGROUND: DSC perfusion has been evaluated in the discrimination between low-grade and high-grade glioma but the diagnostic potential to discriminate beween glioma grades II and III remains unclear. PURPOSE: Our aim was to evaluate the diagnostic accuracy of relative maximal CBV from DSC perfusion MR imaging to discriminate glioma grades II and III. DATA SOURCES: A systematic literature search was performed in PubMed/MEDLINE, Embase, Web of Science, and ClinicalTrials.gov. STUDY SELECTION: Eligible studies reported on patients evaluated with relative maximal CBV derived from DSC with a confirmed neuropathologic diagnosis of glioma World Health Organization grades II and III. Studies reporting on mean or individual patient data were considered for inclusion. DATA ANALYSIS: Data were analyzed by using inverse variance with the random-effects model and receiver operating characteristic curves describing optimal cutoffs and areas under the curve. Bivariate diagnostic random-effects meta-analysis was used to calculate diagnostic accuracy. DATA SYNTHESIS: Twenty-eight studies evaluating 727 individuals were included in the meta-analysis. Individual data were available from 10 studies comprising 190 individuals. The mean difference of relative maximal CBV between glioma grades II and III (n = 727) was 1.76 (95% CI, 1.27-2.24; P < .001). Individual patient data (n = 190) had an area under the curve of 0.77 for discriminating glioma grades II and III at an optimal cutoff of 2.02. When we analyzed astrocytomas separately, the area under the curve increased to 0.86 but decreased to 0.61 when we analyzed oligodendrogliomas. LIMITATIONS: A substantial heterogeneity was found among included studies. CONCLUSIONS:Glioma grade III had higher relative maximal CBV compared with glioma grade II. A high diagnostic accuracy was found for all patients and astrocytomas; however, the diagnostic accuracy was substantially reduced when discriminating oligodendroglioma grades II and III.
Authors: K E Emblem; D Scheie; P Due-Tonnessen; B Nedregaard; T Nome; J K Hald; K Beiske; T R Meling; A Bjornerud Journal: AJNR Am J Neuroradiol Date: 2008-06-26 Impact factor: 3.825
Authors: T B Nguyen; G O Cron; K Perdrizet; K Bezzina; C H Torres; S Chakraborty; J Woulfe; G H Jansen; J Sinclair; R E Thornhill; C Foottit; B Zanette; I G Cameron Journal: AJNR Am J Neuroradiol Date: 2015-07-30 Impact factor: 3.825
Authors: J Gregory Cairncross; Meihua Wang; Robert B Jenkins; Edward G Shaw; Caterina Giannini; David G Brachman; Jan C Buckner; Karen L Fink; Luis Souhami; Normand J Laperriere; Jason T Huse; Minesh P Mehta; Walter J Curran Journal: J Clin Oncol Date: 2014-02-10 Impact factor: 44.544
Authors: Sofie Van Cauter; Frederik De Keyzer; Diana M Sima; Anca Croitor Sava; Felice D'Arco; Jelle Veraart; Ronald R Peeters; Alexander Leemans; Stefaan Van Gool; Guido Wilms; Philippe Demaerel; Sabine Van Huffel; Stefan Sunaert; Uwe Himmelreich Journal: Neuro Oncol Date: 2014-07 Impact factor: 12.300
Authors: Anna Falk; Markus Fahlström; Egill Rostrup; Shala Berntsson; Maria Zetterling; Arvid Morell; Henrik B W Larsson; Anja Smits; Elna-Marie Larsson Journal: Neuroradiology Date: 2014-09-10 Impact factor: 2.804
Authors: Jeanette E Eckel-Passow; Daniel H Lachance; Annette M Molinaro; Kyle M Walsh; Paul A Decker; Hugues Sicotte; Melike Pekmezci; Terri Rice; Matt L Kosel; Ivan V Smirnov; Gobinda Sarkar; Alissa A Caron; Thomas M Kollmeyer; Corinne E Praska; Anisha R Chada; Chandralekha Halder; Helen M Hansen; Lucie S McCoy; Paige M Bracci; Roxanne Marshall; Shichun Zheng; Gerald F Reis; Alexander R Pico; Brian P O'Neill; Jan C Buckner; Caterina Giannini; Jason T Huse; Arie Perry; Tarik Tihan; Mitchell S Berger; Susan M Chang; Michael D Prados; Joseph Wiemels; John K Wiencke; Margaret R Wrensch; Robert B Jenkins Journal: N Engl J Med Date: 2015-06-10 Impact factor: 176.079
Authors: P Darvishi; P P Batchala; J T Patrie; L M Poisson; M-B Lopes; R Jain; C E Fadul; D Schiff; S H Patel Journal: AJNR Am J Neuroradiol Date: 2020-04-23 Impact factor: 3.825
Authors: Antoine Girard; Pierre-Jean Le Reste; Alice Metais; Beatrice Carsin Nicol; Dan Cristian Chiforeanu; Elise Bannier; Boris Campillo-Gimenez; Anne Devillers; Xavier Palard-Novello; Florence Le Jeune Journal: J Neurooncol Date: 2021-10-22 Impact factor: 4.130
Authors: David A Joyner; John Garrett; Prem P Batchala; Bharath Rama; Joshua R Ravicz; James T Patrie; Maria-B Lopes; Camilo E Fadul; David Schiff; Rajan Jain; Sohil H Patel Journal: Neuroradiology Date: 2022-08-12 Impact factor: 2.995